The Use of Memantine for Prevention of Alzheimer's Disease

Summary

As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. AD is caused by the dysfunction, loss of synapses, and eventual neuronal death, which may occur up to 25 years before clinical symptoms appear. This study, based off of pre-clinical data, seeks to assess whether it is feasible to use memantine hydrochloride for the prevention of Alzheimer's Disease.

Timeline

Start

2021-10-11

Primary completion

2026-12

Completion

2026-12

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper No formal hypotheses are included in this feasibility trial. PMID 42179865 ↗

Publications

• Arp AM, Bloom GS, D'Abreu A, Fansler A, Meegan K, Ratcliffe S, Kapur J, Manning C. The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol. Contemp Clin Trials Commun. 2026 May 4;51:101644. doi: 10.1016/j.conctc.2026.101644. eCollection 2026 Jun.

Drugs

Indications